• Charles River reaffirmed 2026 guidance, projecting revenue and non-GAAP EPS at the upper ends of prior ranges.
• Organic revenue growth expected near 1% within the 0%-1% range; non-GAAP operating margin forecast at 21.0%-21.3%.
• Non-GAAP EPS outlook near $11.45 within the $11.15-$11.45 range, citing continued favorable biopharma client demand.
• Introduced 2030 targets: 5%-7% organic revenue CAGR for 2027-2030; non-GAAP operating margin near 24%.
• Targets include low-double-digit non-GAAP EPS CAGR for 2027-2030; Create the Future program aims for over $300 million savings in 2027-2030.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609240800BIZWIRE_USPR_____20260924_BW597077) on September 24, 2026, and is solely responsible for the information contained therein.